These studies did not show any significant benefit on mortality and renal and / or cardiovascular outcomes, while an increased risk of hyperkalemia, acute kidney injury and / or hypotension was observed, compared to monotherapy. Given the similarity of their pharmacological properties, these results are also appropriate for other ACE and ARAII inhibitors.